1 Hu, E., Dul, E., Sung, C., et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307 720-728 (2003).

2 Saito, A., Yamashita, T., Mariko, Y., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96 4592-4597 (1999).

3 Jaboin, J., Wild, J., Hamidi, H., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62 6108-6115 (2002).

4 Xu, J., Zhou, J., Wei, W., et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 68(16) 6718-6726 (2008).

5 Gaymes, T.J., Shall, S., Macpherson, L.J., et al. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 94 638-646 (2009).

6 Nguyen, A., Su, L., Campbell, B., et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma (2009).

MS-275 is available in the following screening libraries:

• Bio-active Lipid I Screening Library (96-Well)
• Epigenetics Screening Library (96-Well)